Heart disease and stroke statistics—2023 update: a report from the American Heart Association
CW Tsao, AW Aday, ZI Almarzooq, CAM Anderson… - Circulation, 2023 - Am Heart Assoc
Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …
2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association
BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …
Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and …
Importance The burden of atherosclerotic cardiovascular disease (ASCVD) in the US is
higher among Black and Hispanic vs White adults. Inclusion of race in guidance for statin …
higher among Black and Hispanic vs White adults. Inclusion of race in guidance for statin …
[HTML][HTML] Trends in lipid-modifying agent use in 83 countries
Background and aims Lipid-modifying agents (LMAs) are increasingly used to reduce lipid
levels and prevent cardiovascular events but the magnitude of their consumption in different …
levels and prevent cardiovascular events but the magnitude of their consumption in different …
PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients
Statins are first-line therapy for treating dyslipidemia because of their low-density lipoprotein
cholesterol (LDL-C) lowering efficacy, superior event-reduction data and unrivaled cost …
cholesterol (LDL-C) lowering efficacy, superior event-reduction data and unrivaled cost …
Prescribing patterns of sodium-glucose cotransporter-2 inhibitors in patients with CKD: a cross-sectional registry analysis
M Zhuo, J Li, LF Buckley, SL Tummalapalli… - Kidney360, 2022 - journals.lww.com
Background Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce kidney disease
progression and mortality in patients with chronic kidney disease (CKD), regardless of …
progression and mortality in patients with chronic kidney disease (CKD), regardless of …
Trends in use and expenditures for brand-name statins after introduction of generic statins in the US, 2002-2018
Importance The high and increasing expenditures for prescription medications in the US is a
national problem. Objective To explore the association of generic statin competition on …
national problem. Objective To explore the association of generic statin competition on …
Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction
Background Adults with atherosclerotic cardiovascular disease (ASCVD) at very high-risk for
recurrent events who have low-density lipoprotein cholesterol≥ 70 mg/dL despite maximally …
recurrent events who have low-density lipoprotein cholesterol≥ 70 mg/dL despite maximally …
Trends in PCSK9 Inhibitor Utilization in the United States, Europe and Other Countries: An Analysis of International Sales Data
First approved in July 2015, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors
are costly lipid-lowering drugs. Their utilization has important policy and clinical implications …
are costly lipid-lowering drugs. Their utilization has important policy and clinical implications …
[HTML][HTML] Is there a role for earlier use of combination therapy?
S Revankar, JK Park, P Satish, A Agarwala - American Journal of …, 2024 - Elsevier
As the global population ages and cardiovascular risk factors rise, we can expect a
continued increase in atherosclerotic disease. Low-density lipoprotein cholesterol (LDL-C) …
continued increase in atherosclerotic disease. Low-density lipoprotein cholesterol (LDL-C) …